Long-term survival of patients with advanced melanoma who received ipilimumab administered at 10 mg/kg every 3 weeks for 4 doses (induction dosing) No significant financial relationships to disclose.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback